← All explainers

Why is HSV so hard to vaccinate against?

Last updated: July 1, 2026

Herpes simplex virus establishes a lifelong dormant infection in nerve cells and carries genes that actively blunt the immune response, so even natural infection does not stop reinfection or recurrences — a vaccine has to outperform what the body manages on its own. This explainer walks through the four obstacles researchers keep hitting: latency, active immune evasion, unknown correlates of protection, and animal models that do not fully mirror human disease. As of 2026, no HSV vaccine is approved.

Herpes simplex virus (HSV) is one of the most widespread human infections, and researchers have been trying to vaccinate against it for the better part of a century. They have not yet succeeded. Understanding why is less a story of any single failure than of four features of the virus that each work against a vaccine at once.

The short answer

HSV is difficult in a way that most vaccine-preventable diseases are not, because the virus does two things the immune system cannot easily counter. It establishes a lifelong latent infection — a dormant state — inside nerve cells, and it carries a set of genes whose job is to actively interfere with the immune response. The consequence is stark: even natural infection does not protect a person from being reinfected or stop the virus from flaring up again [S1][S3]. A vaccine, in other words, has to do better than the immune system manages on its own after real exposure — a higher bar than for most pathogens.

The track record reflects that difficulty. The first attempts to make an HSV vaccine date to the 1920s [S1], and more than 70 years of modern research have followed [S3]. As of 2026, no HSV vaccine — neither prophylactic (given to prevent infection) nor therapeutic (given to control an infection someone already has) — has been approved [S1][S4].

HSV hides where immunity cannot easily reach (latency)

The virus’s first move is to disappear. After the initial lytic infection — the active phase in which HSV replicates in skin or mucosal cells and destroys them — the virus travels up sensory nerves and enters a dormant state inside the ganglia, the clusters of sensory-nerve cell bodies that sit near the spine and skull. There it persists for the life of the host, periodically reactivating and traveling back down the nerve to the surface, where it can shed or cause lesions [S3].

What makes latency so hard to counter is that dormant virus makes little or no protein. The immune system recognizes infected cells largely by the viral proteins they display; a cell harboring silent HSV shows almost nothing, so there is nothing for the immune system to attack and the reservoir cannot be cleared [S3]. This splits the vaccine problem in two. A prophylactic vaccine would need to block latency from ever being established in the first place; a therapeutic vaccine faces the harder task of controlling reactivation from a reservoir the body has already learned to tolerate [S1][S3].

The virus actively fights the immune response (immune-evasion genes)

HSV does not merely hide — it carries dedicated genes that sabotage immune detection and clearance. Several examples are well characterized. The virus interferes with antigen presentation on MHC class I molecules — the display system infected cells use to flag themselves to killer T cells — via a protein (ICP47) that blocks the transporter feeding that pathway [S3]. It disrupts interferon signaling, the early-warning system cells use to raise antiviral defenses [S3]. And it deploys glycoproteins — proteins studded on the viral surface — that blunt the antibody response directly: glycoprotein E (gE) acts as an antibody Fc receptor, grabbing antibodies by their tail end so they cannot properly mark the virus, while glycoprotein C (gC) binds complement, the cascade of blood proteins that helps antibodies destroy pathogens [S3][S6].

The net effect explains an apparent paradox. Natural HSV infection provokes strong antibody and T-cell responses, yet those responses are not sterilizing — they do not eliminate the virus or prevent it from taking hold again [S1][S2]. A vaccine that simply mimics natural infection would inherit the same shortfall.

We do not fully know what protection looks like (unknown correlates)

A further obstacle is that researchers cannot yet reliably measure success in advance. A correlate of protection is a measurable immune response — an antibody level, a particular cell type — that predicts who will be protected. For most successful vaccines, such a correlate is known and can be used to guide design. For HSV it has not been established [S2].

The available evidence complicates the intuitive assumption that more antibody means more protection. Antibody levels in the blood track protection poorly; what appears to matter more is local, tissue-resident T-cell immunity — immune cells that take up long-term residence in the mucosal tissue itself rather than circulating in the blood [S2][S4]. That is a difficult kind of immunity to generate, because a vaccine given by injection primarily raises circulating blood responses, not the stationed tissue-level defenses where HSV actually enters and reactivates [S2][S4].

The 2012 Herpevac trial made these abstractions concrete. This was a Phase 3 efficacy trial — the large, late-stage stage of human testing designed to show whether a vaccine actually works — of a subunit vaccine (one built from a single viral protein, here glycoprotein D from HSV-2, rather than the whole virus). Among 8,323 women who were free of both HSV-1 and HSV-2 at the outset, the vaccine was not efficacious overall: efficacy against genital herpes disease was 20%, a figure whose confidence interval crossed zero and so was not statistically significant [S5]. Yet the same trial showed a genuine split by virus type — the vaccine protected against HSV-1 genital disease (58% efficacy) but showed no protection against HSV-2 disease or infection [S5]. A trial can run to completion, in other words, without the vaccine succeeding at its main goal; the two are not the same thing, and Herpevac’s partial, type-specific result is exactly the kind of outcome the missing correlate of protection would have helped predict.

Cell-to-cell spread and the mucosal front line

Even where antibodies are present, HSV has a route around them. The virus can pass directly from an infected cell to its neighbor, partly shielding itself from neutralizing antibodies — the antibodies that would otherwise intercept free virus particles in transit — because during cell-to-cell spread the virus is never fully exposed in the open [S3][S4]. This reinforces the same lesson as the correlates problem: durable protection likely requires immunity stationed at the mucosal surface, the wet lining of the genital and oral tracts where HSV first lands, rather than immunity confined to the bloodstream [S3][S4].

Animal models do not fully mirror human disease

Finally, the tools used to test candidates before human trials are imperfect stand-ins. Mouse and guinea-pig models do not fully reproduce the human patterns of latency and recurrent disease, so a candidate that looks protective in preclinical (animal) studies frequently does not carry that protection over when it reaches people [S1]. This is one reason promising early results warrant caution rather than confidence: preclinical success and in-human success are distinct milestones, and the gap between them has repeatedly proven wide for HSV.

What this does and does not mean

None of this means an HSV vaccine is impossible. Several candidates are in active development, including approaches that deliberately target the virus’s immune-evasion glycoproteins rather than just its entry machinery. One illustrative line of work is a trivalent design combining glycoproteins C, D and E from HSV-2 (gC2/gD2/gE2): in preclinical studies, adding the immune-evasion antigens to the entry-blocking one improved protection of the nerve ganglia in mice compared with the single-antigen approach [S6]. The same trivalent combination has since been carried into mRNA-based candidates — vaccines that deliver genetic instructions for the target proteins rather than the proteins themselves [S1].

What the evidence does show is that progress is incremental. The obstacles are consistent and well defined: latency, active immune evasion, the unknown correlate of protection, and the imperfect translation from animals to humans. Each candidate that advances addresses some of these while the others remain. No HSV vaccine is approved as of 2026, and any claim that one is imminent runs ahead of what the published evidence supports [S1][S3].